Shanghai, China - September 8, 2025. Shanghai Escugen Biotechnology Co., Ltd. ("Escugen") and Huahui Health (Beijing) Biotechnology Co., Ltd. ("Huahui Health") announced today that they have entered into an exclusive global cooperation and development agreement for a novel, undisclosed tumor target. The partnership aims to jointly develop a potential "First-in-Class" antibody-drug conjugate (ADC) candidate.

On June 16, 2025, Shanghai Escugen Biotechnology and SunRock Biopharma announced a strategic alliance tojoin forces in a strategic partnership to co-develop SRB123, a First-in-Class antibody-drug conjugate (ADC) targeting C-C motif chemokine receptor 9 (CCR9).